Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Boston Scientific Corp.

BSX

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Last trade $43.25
Day change -$0.445 (-1.02%)
Day range $43.03 – $44.01
Volume 6,619,133
Market cap $63.33B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$63.33B
Price / earnings
18.08×
Price / book
2.47×
Price / sales
3.01×
EV / sales
3.54×
EV / EBITDA
12.54×

Profitability

Earnings per share
$2.42
Return on assets
7.7%
Return on equity
13.66%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.47×
Current ratio
1.36×
Quick ratio
0.81×
Cash ratio
0.1×

Cash flow

Price / cash flow
14.96×
Price / free cash flow
19.01×
Free cash flow
$3.33B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BSX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.14B$5.44B$5.2B$5.29B$5.07B$5.06B$4.66B$4.56B
Cost of revenue$1.71B$1.59B$1.59B$1.61B$1.52B$1.64B$1.45B$1.47B
Gross profit$3.43B$3.85B$3.61B$3.68B$3.54B$3.42B$3.21B$3.1B
Selling, general and administrative$1.68B$1.8B$1.78B$1.83B$1.74B$1.72B$1.6B$1.61B
Research and development$520M$554M$516M$569M$514M$526M$443M$459M
Total operating expenses$2.6B$2.67B$2.51B$2.85B$2.49B$2.61B$2.29B$2.42B
Operating income$828M$1.18B$1.1B$825M$1.05B$819M$921M$675M
Interest expense-$100M-$96M-$90M-$90M-$87M-$90M-$82M-$80M
Income before taxes$733M$1.06B$1.16B$700M$939M$941M$805M$585M
Income taxes$153M$155M-$176M$30M$183M$146M$133M$23M
Net income$580M$905M$1.34B$670M$756M$795M$672M$562M
Net income attributable to common shareholders$582M$907M$1.34B$672M$755M$797M$674M$565M
EBITDA$1.37B$1.62B$1.43B$1.53B$1.39B$1.32B$1.34B$1.19B
Basic earnings per share$0.40$0.62$0.90$0.45$0.51$0.54$0.46$0.38
Diluted earnings per share$0.40$0.61$0.90$0.45$0.51$0.53$0.45$0.38

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nerve Repair and Regeneration - Global Market Share Analysis, Industry Trends, Growth Forecasts, 2026-2031 | AI-Enabled Devices and Biomaterials Fuel 11.96% CAGR

The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.

Zacks Investment Research

Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?

Boston Scientific (BSX) lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 due to unexpected headwinds in its WATCHMAN and Electrophysiology franchises. WATCHMAN organic sales fell 5.9% amid weakening demand, while Electrophysiology declined 5.3% due to competitive pressure from Pulsed Field Ablation technologies. The company faces additional challenges from delayed product launches, elevated debt levels, and a cybersecurity incident that accelerated competitive share losses. BSX shares have declined 53.5% year-to-date, significantly underperforming peers and the broader market.

Zacks Investment Research

Coherent and Boston Scientific have been highlighted as Zacks Bull and Bear of the Day

Coherent (COHR) was named Bull of the Day after delivering strong Q1 results with 50% revenue growth, 80% EPS growth, and raised long-term gross margin targets, driven by AI datacenter demand. Boston Scientific (BSX) was named Bear of the Day as it continues to face weak growth outlook with flat 2027 EPS estimates and declining analyst forecasts. CoreWeave (CRWV) reported record Q3 revenues of $3.66B with a $132.5B backlog but faces concerns over high debt levels and mounting interest expenses.

Zacks Investment Research

Bear of the Day: Boston Scientific (BSX)

Boston Scientific reported Q3 organic sales growth of 1.5% that missed guidance due to a cybersecurity disruption, with adjusted EPS falling 3% to 73 cents. The company cut 2026 sales and earnings forecasts, and consensus EPS estimates for 2025 and 2026 have been lowered significantly. Management expects 2027 to be the cycle's trough with recovery anticipated in 2028 driven by new product launches.

Zacks Investment Research

Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown

Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 6, 20032-for-1forward split